CD25 Positive
Showing 1 - 25 of >10,000
Hairy Cell Leukemia Trial run by the NCI (Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin)
Active, not recruiting
- Hairy Cell Leukemia
- Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 13, 2022
CD19+ Relapse/Refractory B-ALL Trial in Beijing (CAR-T-19 Cells)
Recruiting
- CD19+ Relapse/Refractory B-ALL
- CAR-T-19 Cells
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Feb 26, 2022
The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT Trial (CD25
Not yet recruiting
- The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
- CD25 prophylaxis
- (no location specified)
Jun 20, 2023
Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)
Recruiting
- Safety and Efficacy
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Sep 27, 2023
Tregs CD25 CXCL9 in Vitiligo
Not yet recruiting
- Vitiligo
- +3 more
- ELIZA , Flowcytometry
- (no location specified)
Oct 3, 2022
Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)
Recruiting
- Lymphoma
- CD70-targeting CAR-T cells
-
Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, ChinaChina
Jul 9, 2023
CD70-positive Advanced Urologic Tumors Trial in Shanghai (Anti-CD70 CAR-T cells)
Recruiting
- CD70-positive Advanced Urologic Neoplasms
- Anti-CD70 CAR-T cells
-
Shanghai, Shanghai, ChinaChanghai Hospital
Aug 11, 2023
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in United States (ADCT-301)
Terminated
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
-
Atlanta, Georgia
- +10 more
Feb 12, 2020
CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)
Terminated
- CD20-positive Non-Hodgkin Lymphoma
- Rituximab + MG4101
-
Seoul, Korea, Republic ofSeoul National University Hospital
Oct 24, 2022
T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,
Recruiting
- T-cell Acute Lymphoblastic Leukemia
- +3 more
- Universal CD7-specific CAR gene-engineered T cells
-
Beijing, Beijing, China
- +2 more
Aug 17, 2023
Solid Tumor, Adult Trial in Beijing (CD70-targeting CAR-T cells)
Recruiting
- Solid Tumor, Adult
- CD70-targeting CAR-T cells
-
Beijing, Iotherapeutic Department Of Chinsese PLA Gereral Hospital, ChinaChina
Jul 8, 2023
Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer Trial in Nanchang (CD70 CAR-T cells)
Recruiting
- Renal Cell Carcinoma
- +4 more
- CD70 CAR-T cells
-
Nanchang, Jiangxi, ChinaThe First Affiliated Hospital of Nanchang University
Aug 23, 2023
Health Status of Children Born After Assisted Reproductive
Recruiting
- Children Born After Assisted Reproductive Technologies
- +2 more
- hemogram examination
-
Almaty, KazakhstanSevara ilmuratova
Oct 17, 2023
CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)
Recruiting
- CD20-positive Non-Hodgkin Lymphoma
- EX103 injection
-
Zhengzhou, Henan, China
- +3 more
Aug 28, 2023
CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)
Recruiting
- CD20-positive B-cell Non-Hodgkin's Lymphoma
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023
CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,
Not yet recruiting
- CD19-positive Relapsed or Refractory B-cell Malignancies
- UTAA09 cells for infusion
- +2 more
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023
Tumors, Hematologic Tumors, Tumors by Site Trial in Hangzhou (RD13-02 cell infusion)
Recruiting
- Neoplasms
- +3 more
- RD13-02 cell infusion
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Feb 6, 2023
Acute Lymphoblastic Leukemia Trial in Sanhe (CAR-NK-CD19 Cells)
Completed
- Acute Lymphoblastic Leukemia
- CAR-NK-CD19 Cells
-
Sanhe, Hebei, ChinaHebei Yanda Ludaopei Hospital
Nov 24, 2022
Advanced Malignancies Trial in Beijing (1A46 Drug Substance)
Not yet recruiting
- Advanced Malignancies
- 1A46 Drug Substance
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Aug 4, 2023
Acute Lymphoblastic Leukemia Trial in Hangzhou (Blinatumomab)
Recruiting
- Acute Lymphoblastic Leukemia
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Nov 5, 2023
Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory
Active, not recruiting
- Peripheral T Cell Lymphoma
- Pediatric Hodgkin Lymphoma
- Brentuximab Vedotin (Genetical Recombination)
-
Tokyo, JapanTakeda Selected Site
Oct 11, 2022
Acute Myeloid Leukemia Trial in Valencia (AFM28)
Recruiting
- Acute Myeloid Leukemia
-
Valencia, SpainHospital Universitari i Politècnic La Fe
Apr 5, 2023
Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute Trial in Minneapolis (biological, drug, radiation)
Terminated
- Leukemia, Myeloid, Chronic
- +8 more
- Stem Cell Transplant
- +5 more
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Dec 31, 2020
R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,
Recruiting
- R/R CD19-Positive B-Cell Malignancies
- +2 more
- CNTY-101
- +2 more
-
Detroit, Michigan
- +1 more
Dec 21, 2022
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte (procedure, biological, drug,
Recruiting
- Acute Lymphoblastic Leukemia
- +3 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 12, 2023